Resource Summary Report

Generated by RRID on Sep 10, 2026

Recombinant Anti-RAB8A (phospho T72) antibody [MJF-R20]

RRID:AB_2814988
Type: Antibody

Proper Citation

Abcam Cat# ab230260, RRID:AB_2814988

Antibody Information

URL: http://antibodyregistry.org/AB_2814988

Proper Citation: Abcam Cat# ab230260, RRID:AB_2814988

Target Antigen: RAB8A (phospho T72)

Host Organism: rabbit

Clonality: recombinant

Comments: Applications: WB, Dot blot

Antibody Name: Recombinant Anti-RAB8A (phospho T72) antibody [MJF-R20]

Description: This recombinant targets RAB8A (phospho T72)

Target Organism: mouse, human

Clone ID: [MJF-R20]

Antibody ID: AB_2814988

Vendor: Abcam

Catalog Number: ab230260

Record Creation Time: 20231110T032615+0000

Record Last Update: 20260830T005843+0000

Ratings and Alerts

No rating or validation information has been found for Recombinant Anti-RAB8A (phospho T72) antibody [MJF-R20].

No alerts have been found for Recombinant Anti-RAB8A (phospho T72) antibody [MJF-R20].

Data and Source Information

Source: Antibody Registry

Usage and Citation Metrics

We found 14 mentions in open access literature.

Listed below are recent publications. The full list is available at RRID .

Singh K, et al. (2026) Membrane Dysfunction as a Central Mechanism in LRRK2-Associated Parkinson's Disease: Comparative Analysis of G2019S and I1371V Variants. Cells, 15(4).

Goldman A, et al. (2026) An LRRK2 variant blocks NCOA4 trafficking upon iron overload, leading to ferroptotic death. Journal of cell science, 139(14).

Raig ND, et al. (2025) Type-II kinase inhibitors that target Parkinson's Disease-associated LRRK2. bioRxiv : the preprint server for biology.

Raig ND, et al. (2025) Type II kinase inhibitors that target Parkinson's disease-associated LRRK2. Science advances, 11(23), eadt2050.

Dederer V, et al. (2024) A designed ankyrin-repeat protein that targets Parkinson's disease-associated LRRK2. The Journal of biological chemistry, 300(7), 107469.

Dou D, et al. (2024) RAB3 phosphorylation by pathogenic LRRK2 impairs trafficking of synaptic vesicle precursors. The Journal of cell biology, 223(6).

Dou D, et al. (2023) Regulatory imbalance between LRRK2 kinase, PPM1H phosphatase, and ARF6 GTPase disrupts the axonal transport of autophagosomes. Cell reports, 42(5), 112448.

Rinaldi C, et al. (2023) Dissecting the effects of GTPase and kinase domain mutations on LRRK2 endosomal localization and activity. Cell reports, 42(5), 112447.

Kalogeropulou AF, et al. (2022) Impact of 100 LRRK2 variants linked to Parkinson's disease on kinase activity and microtubule binding. The Biochemical journal, 479(17), 1759.

Inoshita T, et al. (2022) Parkinson disease-associated Leucine-rich repeat kinase regulates UNC-104-dependent axonal transport of Arl8-positive vesicles in Drosophila. iScience, 25(12), 105476.

Fdez E, et al. (2022) Pathogenic LRRK2 regulates centrosome cohesion via Rab10/RILPL1-mediated CDK5RAP2 displacement. iScience, 25(6), 104476.

Snead DM, et al. (2022) Structural basis for Parkinson's disease-linked LRRK2's binding to microtubules. Nature structural & molecular biology, 29(12), 1196.

Boecker CA, et al. (2021) Increased LRRK2 kinase activity alters neuronal autophagy by disrupting the axonal transport of autophagosomes. Current biology : CB, 31(10), 2140.

Chen C, et al. (2020) Pathway-specific dysregulation of striatal excitatory synapses by LRRK2 mutations. eLife, 9.